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Abstract An endogenous lipoxygenase inhibitor, purified from
the cytosol of human epidermoid carcinoma A431 cells, was
analyzed by N-terminal microsequencing and mass spectrometric
analysis. The inhibitor was purified by SDS-PAGE, then
subjected to in-gel CNBr cleavage and trypsin digestion. The
N-terminal sequence data obtained from a 6^8 kDa band of in-
gel CNBr cleavage and the three isolated peptides of in-gel
trypsin digestion, and the C-terminal peptide sequence from
matrix-assisted laser desorption ionization mass spectrometry
matched the sequence of human phospholipid hydroperoxide
glutathione peroxidase. The purified inhibitor exhibited perox-
idase activity using phosphatidylcholine hydroperoxides as the
substrate. We therefore concluded that the lipoxygenase inhibitor
present in A431 cells was a phospholipid hydroperoxide
glutathione peroxidase.
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1. Introduction
Oxidative stress is associated with a disturbance in the re-
active oxygen species-antioxidant balance in favor of the for-
mer [1,2]. Many of the reactive oxygen species are oxygen-free
radicals which are involved in the oxidative damage in a num-
ber of physiological and pathophysiological phenomena and
processes as diverse as in£ammation, aging, carcinogenesis,
drug action and drug toxicity. The reactive oxygen species
may be formed from polyunsaturated fatty acids either by
an enzymatic or by a nonenzymatic oxygenation. Reduction
of the reactive oxygen species can be achieved either by the
inhibition of lipid oxygenation enzymes or by the interception
of free radicals by antioxidants and some antioxidation en-
zymes such as superoxide dismutase, catalase and glutathione
peroxidase.
Lipoxygenase and fatty acid cyclooxygenases are the major
enzymes involved in the metabolism of polyunsaturated fatty
acids including arachidonic acid [3]. In studying the regulation
of arachidonate metabolism in human epidermoid carcinoma
A431 cells, we previously reported a putative inhibitor of 12-
lipoxygenase, which masked the biosynthesis of 12(S)-hydrox-
yeicosatetraenoic acid (12(S)-HETE) in intact cells [4]. A sim-
ilar observation was also reported in primary culture of ovine
tracheal epithelial cells [5]. The putative inhibitor in A431 cells
was puri¢ed to a 22 kDa protein whose inhibitory activity was
regulated by the cellular reduction-oxidation (redox) condi-
tions [6]. In addition to 12-lipoxygenase, the inhibitor also
inhibited the activities of 5-lipoxygenase and fatty acid cyclo-
oxygenases in a cell-free system [6]. In the present study, we
performed the sequence analysis of the puri¢ed inhibitor pro-
tein by a high sensitivity microsequencer and mass spectrom-
eter, and found that the sequence data, obtained from a band
of in-gel CNBr cleavage and the three peptides isolated from
in-gel trypsin digestion, and the C-terminal peptide sequence
matched the cDNA sequence of human phospholipid hydro-
peroxide glutathione peroxidase (PHGPx). The puri¢ed inhib-
itor exhibited peroxidase activity using phosphatidylcholine
hydroperoxides as the substrate. We therefore concluded
that the lipoxygenase inhibitor present in human epidermoid
carcinoma A431 cells is PHGPx.
2. Materials and methods
2.1. Materials
Pre-made polyacrylamide slab gels (8U10 cm, 16 or 18%) using
Tris-glycine gradient system were purchased from Novex Inc. (San
Diego, CA, USA). CNBr, phosphatidylcholine, soybean lipoxygenase,
GSH, NADPH, glutathione reductase and puri¢ed glutathione perox-
idase (GSHPx-1) from bovine erythrocytes were from Sigma Chemical
Co (St. Louis, MO, USA). Sequencing grade trypsin was supplied by
Boehringer Mannheim (Mannheim, Germany).
2.2. Puri¢cation of inhibitor
The inhibitor in cytosol of A431 cells was puri¢ed by a series of
column chromatographies using CM Sephadex C-50, Sephadex G-100
SF and Mono P columns according to the methods described previ-
ously [6]. Elution of the inhibitor in the puri¢cation chromatographies
was monitored by the 12-lipoxygenase activity assay [6].
2.3. SDS-PAGE and electroblotting
Sample was separated by reducing SDS-PAGE using 16% slab gels
with an operation voltage set at 125 V for 90 min. Proteins or peptides
separated on the gel were immediately transferred onto a PVDF mem-
brane by an electroblot apparatus. Protein band on the blot, visual-
ized by Coomassie blue staining, was cut out for direct N-terminal
sequence analysis. For in-gel digestion experiments, samples were run
on reducing SDS-PAGE as described and the Coomassie blue-stained
protein bands were excised and washed with distilled water and placed
in a 1.5 ml centrifuge vial for subsequent treatment.
2.4. In-gel trypsin digestion and CNBr cleavage
Procedures for in-gel trypsin digestion were similar to those re-
ported by Merewether et al. [7] and the drying step for the gel bands
was performed according to the methods described by Hellman et al.
[8]. Following the digestion, the digest was extracted twice with 150 Wl
of 50% acetonitrile in 0.1% tri£uoroacetic acid (TFA). Each extraction
proceeded about 30 min with gentle mixing. The combined fraction
was partially dried for peptide mapping.
For in-gel CNBr cleavage, the excised protein band was allowed to
dry under conditions similar to those of in-gel trypsin digestion. The
dried gel was then rehydrated with 10 Wl of 70% formic acid contain-
ing CNBr at a concentration of 200 mg/ml. The partially rehydrated
gel was then transferred to a 0.5 ml vial. Approximately another 25 Wl
of the above-mentioned CNBr solution was added to cover the gel.
The sample was then incubated at 25‡C for 20 h. The digest was then
extracted twice with 150 Wl of 50% acetonitrile in 0.1% TFA. Each
extraction proceeded about 30 min with gentle mixing. The combined
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fraction was completely dried and reconstituted into 30 Wl of SDS-
PAGE sample bu¡er. Electrophoresis was performed using 18% slab
mini-gel and the separated peptides on the gel were transferred onto
PVDF membrane for N-terminal sequence analysis.
2.5. Micro HPLC peptide mapping
The in-gel tryptic digestion sample was separated by reverse-phase
HPLC using a micro-liquid chromatograph (Model 1090, Hewlett
Parkard, CA, USA) equipped with a diode array detector and a
PC-based workstation for data processing. A microbore C4 reverse-
phase column (1.0 mmU10 cm, Synchrom, CA, USA) was equili-
brated with 98% mobile phase A/2% mobile phase B at a £ow rate
of 0.1 ml/min. HPLC mobile phase A consisted of 0.1% TFA in
HPLC-grade water and mobile phase B was 0.1% TFA in 90%
HPLC-grade acetonitrite. The separation of the peptide mixture was
performed by a 70 min linear gradient from the initial equilibration
condition (see above) to 40% mobile phase A/60% mobile phase B at a
£ow rate of 0.1 ml/min. The peptide peaks were detected by UV
absorbance at both 215 and 280 nm. Peptide fractions were manually
collected for further analysis.
2.6. Microsequencing and mass spectrometric analysis
N-terminal amino acid sequence analysis was performed on either
an automatic Procise sequencer or a modi¢ed high sensitivity Procise
sequencer (Applied Biosystem Inc., Foster City, CA, USA) using se-
quencing programs recommended by the vendor with slight modi¢ca-
tion. The on-line PTH amino acid separation was performed using
either a narrow bore C18 column (2.1 mmU25 cm) for the Procise
sequencer or a microbore C18 column (0.8 mmU25 cm) for the high
sensitivity modi¢ed Procise sequencer under conditions recommended
by the vendor. In the latter case, the detection and quanti¢cation of
PTH amino acids can be obtained at 50 femtomole level using micro-
bore HPLC separation.
Matrix-assisted laser desorption ionization mass spectrometry
(MALDI-MS) of peptides was performed on a Kompact MALDI
IV mass spectrometer (Kratos Analytical, Ramsey, NJ, USA)
equipped with a curved ¢eld re£ectron and a precursor ion gate ac-
cording to Jones et al. [9]. Aliquots of sample (0.7 Wl) and matrix
solution (0.4 Wl of K-cyano-4-hydroxycinnamic acid; 33 mM in ace-
tonitrile/methanol/water, 5:3:2 v/v) were properly mixed and spotted
onto the probe slide. Following an air-dry step, the sample was ready
for analysis. Spectra were obtained in either the linear mode, at an
acceleration voltage of 20 kV, or the re£ector mode, with the linear
voltage at 20 kV and the ion mirror set at 21 kV. The MALDI IV
laser power can be adjusted from a relative scale (from 0 to 180) set
by the manufacturer, in which the threshold of detection ranged from
45 to 65 in the linear mode and from 85 to 105 in the re£ectron mode
for postsource decay of a selected molecular ion. The naming system
of fragment ions uses the traditional a, b, and c series of ions if the
charge is retained on the N-terminus as well as x, y, and z series of
ions if the charge is on the C-terminus, which are followed by a sub-
script number indicating the position of the fragmentation in the
peptide backbone [10].
2.7. Activity assay of PHGPx
Phospholipid hydroperoxides were prepared by incubating phos-
phatidylcholine with soybean lipoxygenase, followed by separation
with a Sep-Pak C18 cartridge according to the methods described by
Maiorino et al. [11]. PHGPx activity was measured by recording the
disappearance of absorbance of NADPH at 340 nm in the presence of
GSH, glutathione reductase and phosphatidylcholine hydroperoxides
as previously described [11]. Brie£y, the reaction mixture in a ¢nal
volume of 1 ml contained 3 mM GSH, 0.1 mM NADPH, 1.2 units of
glutathione reductase, 5 mM EDTA, 0.12% (v/v) Triton X-100 and
sample of PHGPx in 100 mM Tris bu¡er (pH 7.4). The enzymatic
reaction was started by the addition of 10V30 WM phosphatidylcho-
line hydroperoxides. One unit of activity was de¢ned by the reduction
of 1 nmol/min at 37‡C.
3. Results
3.1. N-terminal block of the 22 kDa protein
When compared to the standard proteins, the Coomassie
blue-stained intensity of a 22 kDa protein band blotted onto
PVDF membrane shown in Fig. 1, suggested that the sample
amount is between 0.5^1.0 Wg (or 20^45 pmol range). This
PVDF blot was cut out and subjected to high sensitivity mi-
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Fig. 1. SDS-PAGE and electroblotting of puri¢ed protein. Sample
(3 Wg of protein) puri¢ed by a series of column chromatographies
including CM Sephadex C-50, Sephadex G-100 SF and Mono P
was analyzed by 16% SDS-PAGE, and then transferred onto a
PVDF membrane. Proteins were visualized by Coomassie blue stain-
ing. Positions of molecular mass markers are given on lane A and
the position of the puri¢ed 22 kDa protein is given on lane B.
Table 1
Sequence yield of an in-gel CNBr-digested peptide
Cycle Amino acid identi¢ed
Major sequence (fmol recovered)a Secondary sequenceb
1 Lys (320) Val
2 Ile (200) Asn
3 Gln (200) Leu
4 Pro (120) Asp
5 Lys (100) ^
6 Gly (100) Tyr
7 Lys (80) Arg
8 Gly (80) Gly
9 Ile (70) Phe
10 Leu (60) Val
A 6^8 kDa band, obtained from in-gel CNBr digestion of 22 kDa protein on PVDF membrane was analyzed by a high sensitivity protein sequencer
(see Section 2).
aSequence yields in femtomole were background corrected.
bThe yield was not calculated.
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crosequencer analysis. However, no clear signal above 0.2
pmol level at the ¢rst sequencing cycle could be detected
and no sequence could be identi¢ed in the following cycles
(data not shown). This low sequencing yield indicated this
protein may be N-terminally blocked. Another 22 kDa pro-
tein blot was subsequently subjected to CNBr cleavage and
sequencing of the cleaved products. Several clear mixed sig-
nals at 1^2 pmol levels were detected, clearly indicating that
the protein was indeed blocked at its N-terminus. The nature
of the blockage is unknown.
3.2. In-gel CNBr cleavage, isolation and sequence analysis of
CNBr peptides
In a separate experiment, a second sample was also sub-
jected to SDS-PAGE. The 22 kDa protein described above
was isolated by cutting out two gel bands. These two bands
were combined and subjected to in-gel CNBr digestion. The
CNBr digested peptides were separated on a 18% reducing
SDS-PAGE gel then blotted onto PVDF. The peptides near
22 kDa, 10 kDa, 6^8 kDa were barely visible after staining
(data not shown). The 6^8 kDa band was then sequenced by
high sensitivity sequencer, a major sequence and a minor se-
quence were detected with sequencing yield listed in Table 1.
3.3. In-gel trypsin digestion, peptide mapping and sequence
analysis
Fig. 2 shows a peptide map from micro HPLC of a tryptic
peptide mixture obtained from in-gel trypsin digestion of two
22 kDa protein bands. Several peaks were detected at 215 nm.
A negative peak near 44 min retention time was the remaining
Coomassie blue dye. About one third of the fraction from
four peaks was directly sequenced. Three peaks with retention
times at 21 min, 25 min and 27 min showed very clean se-
quences as indicated in Fig. 2. One peak with retention time at
38 min was detected to have no sequence signals and no mass
spectrum, suggesting it might be an artifact peak. Several
other small peaks were not analyzed because some of these
peaks may be related to trypsin peptides derived from trypsin
autolysis during digestion.
3.4. Mass spectrometric analysis
The obtained amino acid sequence of a tryptic peptide at 27
min retention time did not contain either a lysine or arginine
at the C-terminus, indicating that it may be a C-terminal
peptide of the protein. This was further con¢rmed by MAL-
DI-MS analysis shown in Fig. 3. By MALDI-MS analysis in a
linear mode, the peptide was determined to have a proto-
nated, averaged mass of 792.2 dalton (Fig. 3A) which
matched the expected mass of 791.9 dalton. Following post-
source decay of the selected molecular ion (i.e. 792.2 dalton)
in re£ectron mode, a number of fragments were generated and
can be assigned to various b and y series of sequence ions as
well as several internal fragment ions with a standard error of
þ 0.3 dalton (Fig. 3B). The determined sequence (Fig. 3C)
completely matched the sequence obtained from automatic
Edman degradation described above.
3.5. Sequence identity to human PHGPx
With a BLASTP search of the SWISS-PROT database, the
sequence data, obtained from the 6^8 kDa band of in-gel
CNBr cleavage (Table 1) and the three isolated peptides of
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Fig. 2. Micro HPLC peptide mapping. The in-gel trypsin-digestive
sample was separated by reverse-phase HPLC using a micro-liquid
chromatography [7]. The peptide fractions were collected for micro-
sequencing. The sequence data of three peptides are indicated re-
spectively. CBB dye indicates the remaining Commassie blue dye.
Fig. 3. MALDI-MS analysis of tryptic peptide at 27 min retention
time. A: MALDI-MS analysis in linear mode for molecular mass
measurement of the peptide (see Fig. 2). B: MALDI-MS postsource
decay for fragmentation of the 792.2 dalton molecular ion. The as-
signed b, and y fragment ions, and a5 ion, and internal fragments
are indicated. C: The assigned peptide sequence using the obtained
fragment ions shown in panel B.
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in-gel trypsin digestion (Fig. 2), matched the protein sequence
of human PHGPx [12]. The obtained C-terminal peptide se-
quence also matched the C-terminus of human PHGPx, indi-
cating that both proteins contain an identical C-terminus.
3.6. PHGPx activity in puri¢ed inhibitor
The PHGPx activity of the lipoxygenase inhibitor obtained
from a series of column chromatographies including CM Se-
phadex G-50, Sephadex G-100 SF and Mono P was studied.
The inhibitor was puri¢ed to 22 kDa by this series of column
chromatographies [6]. The puri¢ed inhibitor exhibited PHGPx
activity in accordance with its 12-lipoxygenase inhibitory ac-
tivity (Fig. 4). At this puri¢cation stage, PHGPx accounted
for 90^100% of the proteins on SDS-PAGE [6], and the spe-
ci¢c activity of PHGPx was approximately 6.2 Wmol/min/mg
at 37‡C. We have previously reported that the 12-lipoxygenase
inhibitory activity of inhibitor was inactivated by iodoacetate
[6]. Treatment of the puri¢ed inhibitor with 2 mM iodoacetate
for 5 min also completely abolished the PHGPx activity (data
not shown). Under the present assay conditions, no PHGPx
activity was observed with 10 Wg of puri¢ed glutathione per-
oxidase (GSHPx-1) of bovine erythrocytes (data not shown),
indicating that the peroxidase assay was speci¢c to PHGPx.
4. Discussion
Two pieces of evidence were obtained from this study in-
dicating that the 22 kDa lipoxygenase inhibitor in A431 cells
was a human PHGPx. Firstly, the peptides isolated from the
in-gel CNBr cleavage and trypsin digestion of the 22 kDa
inhibitor so far matched the cDNA sequence of human
PHGPx cloned from human testis cDNA library [12]. In
addition, the obtained C-terminal peptide sequence from
MALDI-MS also matched the C-terminus of human PHGPx.
In the N-terminal sequence analysis, the N-terminal blockage
was observed in the 22 kDa inhibitor, which was also reported
in porcine PHGPx [13]. Secondly, the puri¢ed lipoxygenase
inhibitor exhibited PHGPx activity when phosphatidylcholine
hydroperoxides were used as the substrate. Treatment of the
puri¢ed protein with iodoacetate completely abolished the
phospholipid hydroperoxide-reduced activity.
PHGPx, a selenium-dependent glutathione peroxidase, be-
longs to glutathione peroxidase family which consists of ¢ve
isozymes. They are: (a) the classical cellular glutathione per-
oxidase GSHPx-1 [14], (b) the phospholipid hydroperoxide
glutathione peroxidase PHGPx [11], (c) the plasma gluta-
thione peroxidase GSHPx-P [15], (d) the gastrointestinal glu-
tathione peroxidase GSHPx-GI [16], and (e) the epididymal
glutathione peroxidase GSHPx-5 [17]. Among these isozymes,
PHGPx is unique in the substrate speci¢city because it can
interact with lipophilic substrates including the peroxidized
phospholipids and cholesterol and reduce these hydroperoxide
to hydroxide compounds [18,19]. Several pieces of evidence
have been provided to indicate the inhibition of lipoxygenases
and fatty acid cyclooxygenase activities by PHGPx. The
present results together with our previous results [6] clearly
indicate that PHGPx inhibits the enzymic activities of 12-lip-
oxygenase, 5-lipoxygenase and cyclooxygenases in a cell-free
system. Schnurr et al. [20] recently reported that PHGPx in-
hibits 15-lipoxygenase activity in vitro and indicated that the
inhibition is probably due to the reduction of hydroperoxy
lipids necessary as an activator for the 15-lipoxygenase activ-
ity. The in vitro activation of the fatty acid cyclooxygenase
[21] and the soybean lipoxygenase [22^24] by fatty acid hydro-
peroxides has been studied in detail. Although limited infor-
mation is available on the mechanism of hydroperoxide
activation of mammalian lipoxygenases, reduction of arach-
idonate hydroperoxides, which are the initial products of
arachidonic acid catalyzed by lipoxygenases and fatty acid
cyclooxygenase, might be a common mechanism for the in-
hibition of enzyme activity by PHGPx.
In A431 cells with epidermal growth factor-induced expres-
sion of 12-lipoxygenase and fatty acid cyclooxygenase, when
challenged with calcium ionophore A23187, prostaglandin E2
formation increased by 3-fold but 12(S)-HETE remained un-
changed [4]. These results suggest that 12-lipoxygenase, but
not fatty acid cyclooxygenase, was down-regulated by the in-
hibitor, PHGPx, in intact cells. Localization of fatty acid cy-
clooxygenase in the lumina of endoplasmic reticulum and nu-
clear envelope [25^28] may prevent fatty acid cyclooxygenase
from interacting with the cytosolic PHGPx in intact A431
cells. In another intact cell system, PHGPx was also reported
to be the primary enzyme for the inhibitory regulation of 5-
lipoxygenase activity in RBL-1 cells [29]. These results provide
a signi¢cant evidence indicating that the activity of lipoxygen-
ases can be regulated by the presence of PHGPx in intact
cells. Brigelius-Floh et al. [30] recently reported that overex-
pression of PHGPx in a human endothelial cell line inhibits
interleukin-1-induced nuclear factor kappaB activation. How-
ever, information on the physiological role of PHGPx is still
very limited and needs further studies.
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Fig. 4. PHGPx activity of puri¢ed inhibitor. The concentrated sam-
ple (997 Wg of protein) obtained from column chromatographies of
CM Sephadex C-50 and Sephadex G-100 SF was applied to a col-
umn (HP 5/20) of Mono P equilibrated with running bu¡er (50 mM
ammonium acetate/1 mM DTT, pH 8). The proteins were eluted
with elution bu¡er (Polybu¡er 96 with 1:20 dilution in the presence
of 1 mM DTT, pH 5.3). The £ow rate was 0.5 ml/min. Each frac-
tion, with a volume of 1 ml, was collected, and 30 Wl of each frac-
tion was used in the 12-lipoxygenase activity inhibitory assay [6]
and 100 Wl of each fraction was used in the PHGPx activity assay,
respectively.
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